Psychiatric Genomics: An Update and an Agenda

By Patrick F. Sullivan, A. Agrawal, C. Bulik, O. Andreassen, A. Børglum, G. Breen, S. Cichon, H. Edenberg, Stephen V. Faraone, Joel Gelernter and 4 more. bioRxiv, 2017

635 citations recorded by the source corpus.

The Psychiatric Genomics Consortium (PGC) is the largest consortium in the history of psychiatry. In the past decade, this global effort has delivered a rapidly increasing flow of new knowledge about the fundamental basis of common psychiatric disorders, particularly given its dedication to rapid progress and open science. The PGC has recently commenced a program of research designed to deliver “actionable” findings - genomic results that (a) reveal the fundamental biology, (b) inform clinical practice, and (c) deliver new therapeutic targets. This is the central idea of the PGC: to convert the family history risk factor into biologically, clinically, and therapeutically meaningful insights. The emerging findings suggest that we are entering into a phase of accelerated translation of genetic discoveries to impact psychiatric practice within a precision medicine framework. Collaborators PGC Coordinating Committee: Mark Daly, Michael Gill, John Kelsoe, Karestan Koenen, Douglas Levinson, Cathryn Lewis, Ben Neale, Danielle Posthuma, Jonathan Sebat, and Pamela Sklar.

Subfields: Genetics

View Paper: https://www.semanticscholar.org/paper/2467d8de8b47c72b0a0e7693be6b2529d9375919

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

Citations in the corpus

Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments (2019, background): “The relatively low rate of heritability, approximately 37%, the absence of variants with substantial impact on depression risk, the polygenic nature of depression risk, and the heterogeneity of depression, have contributed to the difficulty in identifying genetic determinants of susceptibility (Flin”
An expanded view of complex traits: from polygenic to omnigenic (2017, background): “…in terms of both the importance of the largest-effect common variants and of higher-penetrance rare variants (Loh et al., 2015; Shi et al., 2016; Sullivan et al., 2017), it is now clear that polygenic effects are important across a wide variety of traits (Shi et al., 2016; Weiner et al., 2016).”
Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders (2019, background): “Many risk loci have emerged from genome-wide association studies (GWAS) of, among others, schizophrenia (SCZ), bipolar disorder (BIP), major depression (MD), and attention-deﬁcit/hyperactivity disorder (ADHD) from the Psychiatric Genomics Consortium (PGC) and other efforts (Sullivan et al., 2018).”